Spruce Street Capital LP Acquires New Shares in Savara Inc. $SVRA

Spruce Street Capital LP bought a new position in shares of Savara Inc. (NASDAQ:SVRA) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,452,576 shares of the company’s stock, valued at approximately $21,267,868,000. Savara makes up 4.2% of Spruce Street Capital LP’s investment portfolio, making the stock its 8th biggest holding. Spruce Street Capital LP owned approximately 1.68% of Savara at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of SVRA. Algert Global LLC boosted its position in shares of Savara by 53.7% in the 2nd quarter. Algert Global LLC now owns 1,329,259 shares of the company’s stock worth $8,188,000 after buying an additional 464,645 shares in the last quarter. Sanctuary Advisors LLC purchased a new position in Savara during the 2nd quarter valued at about $87,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Savara during the 2nd quarter valued at about $461,000. E Fund Management Co. Ltd. purchased a new position in Savara during the 2nd quarter valued at about $77,000. Finally, DCF Advisers LLC acquired a new position in Savara during the second quarter worth about $616,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on SVRA shares. Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.14.

Savara Stock Performance

Savara stock opened at $5.56 on Tuesday. The stock has a fifty day moving average price of $5.70 and a 200 day moving average price of $5.47. Savara Inc. has a 52 week low of $3.08 and a 52 week high of $7.01. The firm has a market capitalization of $1.14 billion, a P/E ratio of -9.59 and a beta of 0.29. The company has a current ratio of 10.13, a quick ratio of 10.13 and a debt-to-equity ratio of 0.21.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Equities research analysts anticipate that Savara Inc. will post -0.62 earnings per share for the current year.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.